Elucidation of the mechanisms involved in cancer’s manipulation and evasion of the
immune system has opened the door for new immunotherapy targets to promote an antitumor
response.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Clinical RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Primer on tumor immunology and cancer immunotherapy.J Immunother Cancer. 2013; 1: 12
- Resistance to PD1/PDL1 checkpoint inhibition.Cancer Treat Rev. 2017; 52: 71-81
- Molecular biology of the cell.4th edition. Garland Science, New York2002
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression.Clin Exp Immunol. 2013; 171: 36-45
- Immuno-oncology and Its opportunities for interventional radiologists: immune checkpoint inhibition and potential synergies with interventional oncology procedures.J Vasc Interv Radiol. 2017; 28: 1487-1494
- CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes.J Exp Med. 1992; 175: 353-360
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.Immunity. 1995; 3: 541-547
- CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition.Am J Clin Oncol. 2016; 39: 98-106
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.Immunol Rev. 2008; 224: 166-182
- Metabolic exhaustion in infection, cancer and autoimmunity.Nat Immunol. 2018; 19: 213-221
- The chronicles of T-cell exhaustion.Nature. 2017; 543: 190
- T-cell exhaustion in the tumor microenvironment.Cell Death Dis. 2015; 6: e1792
- Reversing T-cell dysfunction and exhaustion in cancer.Clin Cancer Res. 2016; 22: 1856-1864
- Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization.Gastroenterology. 2008; 134 (1937.e1921-1922): 1927-1937
- Role of tumor microenvironment in tumorigenesis.J Cancer. 2017; 8: 761-773
- The tumor microenvironment and its role in promoting tumor growth.Oncogene. 2008; 27: 5904-5912
- Combination cancer immunotherapies tailored to the tumour microenvironment.Nat Rev Clin Oncol. 2015; 13: 143
- Contribution of regulatory T cells to cancer: a review.J Cell Physiol. 2019; 234: 7983-7993
- Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity.Cell Rep. 2018; 23: 3262-3274
- Oncogenic BRAF(V600E) governs regulatory t-cell recruitment during melanoma tumorigenesis.Cancer Res. 2018; 78: 5038-5049
- Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.Cancer. 2010; 116: 2224-2233
- Immune surveillance by the liver.Nat Immunol. 2013; 14: 996-1006
- Immunotherapy in hepatocellular carcinoma: primed to make a difference?.Cancer. 2016; 122: 367-377
- Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance.Hepatology. 2008; 47: 296-305
- Liver inflammation abrogates immunological tolerance induced by Kupffer cells.Hepatology. 2015; 62: 279-291
- Chronically inflamed livers up-regulate expression of inhibitory B7 family members.Hepatology. 2009; 50: 1625-1637
- Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.Hepatology. 2014; 60: 1776-1782
- Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis.PloS One. 2011; 6: e24671
- Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.J Clin Oncol. 2007; 25: 2586-2593
- Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases.World J Gastroenterol. 2006; 12: 3716-3721
- Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization.J Immunol. 2007; 178: 1914-1922
- Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response.Gastroenterology. 2010; 138: 1931-1942
- Immuno-thermal ablations - boosting the anticancer immune response.J Immunother Cancer. 2017; 5: 78
- Current tumor ablation technologies: basic science and device review.Semin Intervent Radiol. 2010; 27: 247-254
- PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor.Clin Cancer Res. 2016; 22: 1173-1184
- Potential of radiofrequency ablation in combination with immunotherapy in the treatment of hepatocellular carcinoma.J Clin Trials. 2016; 6 ([pii:257])
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.Hepatology. 2013; 57: 1448-1457
- Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.Cancer Res. 2012; 72: 430-439
- In situ tumor ablation creates an antigen source for the generation of antitumor immunity.Cancer Res. 2004; 64: 4024-4029
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol. 2017; 66: 545-551
- Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma.Int J Cancer. 2010; 126: 2164-2174
- Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1alpha for hepatocellular carcinoma: a preliminary study of rat model.J Cancer Res Clin Oncol. 2017; 143: 199-207
- PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.J Exp Med. 2014; 211: 781-790
- Peripheral blood regulatory T-cell and type 1 helper T-cell population decrease after hepatic artery embolization.J Vasc Interv Radiol. 2016; 27: 1561-1568
- Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.Gut. 2019; 68: 335-346
- Combined effects of yttrium-90 transarterial radioembolization around immunotherapy for hepatic metastases from uveal melanoma: a preliminary retrospective case series.J Vasc Interv Radiol. 2018; 29: 1369-1375
- Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography.Am J Clin Oncol. 2016; 39: 189-195
- Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma.Cardiovasc Intervent Radiol. 2018; 41: 1799-1802
- Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy.Cancer Cell. 2013; 24: 589-602
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.J Exp Med. 2006; 203: 1259-1271
- Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.J Clin Invest. 2014; 124: 687-695
Article info
Publication history
Published online: June 11, 2019
Footnotes
Disclosure Statement: R. Hickey is a consultant for BTG International and Bayer Pharmaceuticals.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
